柠檬酸镁(Magnesium citrate) - 在研适应症：肠道准备，原发性高血压，高血压_专利_临床

概要

基本信息

简介柠檬酸镁是一种由镁和柠檬酸以1:1的比例混合而成的小分子药物，被批准用于在结肠检查期间排除肠内容物和作为腹部手术的预处理泻药。柠檬酸镁的商品名有 Magcorol 和 Tectlol，该药物由 RMJ Holdings 制造，并于 1973 年 4 月 28 日首次在日本获得批准。柠檬酸镁的作用是将水分吸引到肠道并促进排便，从而清理肠道。它通常用于结肠镜检查或其他需要清洁肠道的医疗程序之前的肠道准备。柠檬酸镁可以液体或片剂形式在柜台销售，也可以药丸形式用作镁膳食补充剂。

药物类型

小分子化药

别名

Magnesium citrate (JAN/USP)、Magnesium citrate (RMJ Holdings)、Magnesium dicitrate

+ [6]

靶点-

作用机制-

治疗领域

其他疾病心血管疾病

在研适应症

肠道准备原发性高血压高血压

非在研适应症-

原研机构

RMJ Holdings, Inc.

在研机构

Horii Pharmaceutical Ind., LTD.RMJ Holdings, Inc.RMJ SGRpA

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1973-04-28),

肠道准备

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C6H8MgO7

InChIKeyROYPGAQNKYWYDI-UHFFFAOYSA-N

CAS号3344-18-1

查看全部结构式(2)

关联

12

项与柠檬酸镁相关的临床试验

JPRN-jRCTs041210067 / Not yet recruiting临床3期IIT

Efficacy and tolerability of elobixibat plus sodium picosulfate with magnesium citrate versus split dose 2-L polyethylene glycol with ascorbic acid for bowel preparation before outpatient colonoscopy:A multicenter, randomized controlled trial

开始日期2021-12-06

申办/合作机构-

NCT04930237 / WithdrawnN/AIIT

RELISTOR's Effects on Opioid-Induced Constipation in Postoperative 1-2 Level Anterior Lumbar Interbody Fusion Patients: A Case-Control Study

This will be a prospective case-control study of 40 patients undergoing 1-2 level ALIF procedures at Methodist Dallas Medical Center (MDMC). Patient records will be reviewed to identify details including demographics, comorbidities, procedure details, and the primary and secondary outcome metrics.

开始日期2021-07-01

申办/合作机构

Methodist Health System, Inc.

KCT0003662 / RecruitingN/A

Surgical site infection after bowel preparation for colorectal cancer with Sodium picosulfate and Magnesium citrate versus Clicool powder : A Randomized Non-inferiority Trial

开始日期2019-07-03

申办/合作机构

Kyungpook National University Medical Center

100 项与柠檬酸镁相关的临床结果

登录后查看更多信息

100 项与柠檬酸镁相关的转化医学

登录后查看更多信息

100 项与柠檬酸镁相关的专利（医药）

登录后查看更多信息

502

项与柠檬酸镁相关的文献（医药）

2024-10-01·Journal of Gastroenterology and Hepatology

Efficacy and safety of same‐day preparation with sodium picosulfate plus magnesium citrate on the day of colonoscopy for bowel preparation: Multicenter, single‐arm, open‐label study

Article

作者: Miyazaki, Haruka ; Fujisawa, Mizuho ; Takao, Madoka ; Kodama, Yuzo ; Takayama, Hiroshi ; Kinoshita, Masato ; Ueda, Chise ; Ikezawa, Nobuaki ; Toyonaga, Takashi ; Yoshizaki, Tetsuya ; Hori, Hitomi ; Hoki, Shinya ; Sakaguchi, Hiroya ; Morita, Yoshinori ; Abe, Hirofumi ; Ooi, Makoto ; Ishida, Ryosuke ; Okamoto, Norihiro ; Tanabe, Hiroshi ; Tanaka, Shinwa

AbstractBackground and AimSodium picosulfate plus magnesium citrate (SP + MC) is a well‐tolerated bowel preparation agent. However, Japan currently approves only two methods of taking SP + MC: the day‐before and split‐dose preparation, without approval of same‐day preparations. This study aimed to evaluate the efficacy and safety of same‐day SP + MC preparations.MethodsThis was a multicenter, single‐arm, nonrandomized, open‐label study. We enrolled 145 Japanese patients between June and December 2023. The patients received two sachets of SP + MC dissolved in 300 ml of water and 1200 mL or more of clear liquid on the day of colonoscopy. Bowel cleansing efficacy, adverse events (AEs), and patient satisfaction were evaluated.ResultsOf the enrolled patients, 137 underwent colonoscopy according to our protocol. Bowel preparation was adequate in 133 patients (97.1%). The mean total Boston Bowel Preparation Score was 8.3 ± 1.2. Five patients experienced AEs (3.6%): two (1.5%), abdominal pain; one (0.73%), ischemic enteritis; one (0.73%), vomiting or nausea; and one (0.73%), headache. All AEs were treated conservatively. None of the patients exhibited abnormal blood test results or clinical symptoms after receiving SP + MC. Regarding patient satisfaction, all patients were able to take SP + MC as directed; 136 (99.2%) expressed a preference for this bowel preparation for future colonoscopies.ConclusionThe same‐day SP + MC preparation showed high bowel‐cleansing efficacy and satisfaction in Japanese patients without serious AEs.

2024-10-01·Therapeutic Apheresis and Dialysis

Factors affecting clinical outcomes of continuous and intermittent plasmapheresis in patients with severe hypertriglyceridemia

Article

作者: Hussein, Eiman A.

AbstractIntroductionAcute hypertriglyceridemia is considered a category III indication for plasmapheresis. The use of plasma as replacement fluid (RF) has been suggested to replace the consumed lipoprotein lipase. Heparin when used as an anticoagulant could possibly release lipoprotein lipase, thereby increasing triglyceride clearance.MethodsThe impact of RF (albumin vs fresh frozen plasma (FFP) and anticoagulant (ACD‐A vs. heparin) on triglycerides following plasmapheresis in 27 patients with severe hypertriglyceridemia (SHTG) was investigated. A paired study of four patients with recurrent SHTG was conducted, evaluating continuous (Optia) versus intermittent flow plasmapheresis (Haemonetics).ResultsShorter procedures positively impacted triglycerides (TG) drop post‐sessions p < 0.05. In albumin sessions, patients who used heparin demonstrated significantly greater drop in TG and required less sessions than did those with citrate p < 0.05. In heparin sessions, patients who used albumin demonstrated significantly greater drop in triglycerides and required less sessions than did those with FFP p < 0.05. Three of six patients who used FFP and heparin showed a triglyceride drop of 11.7% following three sessions and a 50% drop with one albumin session. Compared with Haemonetics, Optia removed comparable volumes of plasma in less time, processing smaller blood volumes and using less citrate p < 0.05. Patients demonstrated significantly lower drop in TG and required more sessions with Haemonetics than they did with Optia p < 0.05.ConclusionShorter procedure was the main predictor for effective TG clearance. This can be achieved by continuous apheresis technology, particularly when using albumin as RF. TG removal via Optia seems to be optimized by using heparin.

2024-09-01·Advanced Healthcare Materials

Metabolic Control During Macrophage Polarization by a Citrate‐Functionalized Scaffold for Maintaining Bone Homeostasis

Article

作者: Hong, Chuhang ; Wei, Wenying ; Xia, Yuhao ; Wu, Xiaopei ; Dai, Honglian ; Zhao, Yanan ; Zheng, Dian

AbstractMetabolites, as markers of phenotype at the molecular level, can regulate the function of DNA, RNA, and proteins through chemical modifications or interactions with large molecules. Citrate is an important metabolite that affects macrophage polarization and osteoporotic bone function. Therefore, a better understanding of the precise effect of citrate on macrophage polarization may provide an effective alternative strategy to reverse osteoporotic bone metabolism. In this study, a citrate functional scaffold to control the metabolic pathway during macrophage polarization based on the metabolic differences between pro‐inflammatory and anti‐inflammatory phenotypes for maintaining bone homeostasis, is fabricated. Mechanistically, only outside M1 macrophages are accumulated high concentrations of citrate, in contrast, M2 macrophages consume massive citrate. Therefore, citrate‐functionalized scaffolds exert more sensitive inhibitory effects on metabolic enzyme activity during M1 macrophage polarization than M2 macrophage polarization. Citrate can block glycolysis‐related enzymes by occupying the binding‐site and ensure sufficient metabolic flux in the TCA cycle, so as to turn the metabolism of macrophages to oxidative phosphorylation of M2 macrophage, largely maintaining bone homeostasis. These studies indicate that exogenous citrate can realize metabolic control of macrophage polarization for maintaining bone homeostasis in osteoporosis.

100 项与柠檬酸镁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03265	柠檬酸镁	-	DB11110

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肠道准备	日本	Horii Pharmaceutical Ind., LTD.	1973-04-28

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性高血压	临床3期	日本	RMJ Holdings, Inc.	2022-01-30
高血压	临床2期	-	RMJ SGRpA	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02977286 (CTgov)	临床4期	便秘	12	Polyethylene Glycols+Magnesium Citrate Oral Liquid Product+Bisacodyl 10 mg Suppository+Docusate Sodium 100 Mg oral capsule [Colace]+Senna 217 Mg Oral Tablet+Naloxegol Oral Tablet+Methylnaltrexone (Naloxegol Oral Tablet)	範網壓憲繭壓鬱窪鏇築(鹽齋鏇製齋願鏇淵繭積) = 窪鏇壓窪選醖廠遞鬱艱蓋顧鹹膚醖憲衊廠糧鬱 (簾鑰構壓觸觸築遞範壓, 簾廠繭築淵製齋簾壓鹽 ~ 製襯餘築夢蓋鬱顧齋齋) 更多	-	2023-02-16
NCT02977286 (CTgov)	临床4期	便秘	12	Placebo Oral Tablet+Magnesium Citrate Oral Liquid Product+Bisacodyl 10 mg Suppository+Docusate Sodium 100 Mg oral capsule [Colace]+Senna 217 Mg Oral Tablet+Methylnaltrexone (Placebo Oral Tablet)	範網壓憲繭壓鬱窪鏇築(鹽齋鏇製齋願鏇淵繭積) = 築範鹽積齋獵簾醖願糧蓋顧鹹膚醖憲衊廠糧鬱 (簾鑰構壓觸觸築遞範壓, 遞鏇築積範醖淵簾鹹齋 ~ 廠繭襯醖鹹鹹鬱積衊廠) 更多	-	2023-02-16
WCN2015	N/A	2型糖尿病	100	Magnesium dicitrate	艱顧蓋醖願築繭鏇簾顧(齋襯範選餘鹹餘糧鹹遞) = 築鹹鹽醖膚衊網膚構鏇獵壓鹹膚觸壓範顧鹹窪 (壓積醖鹽鏇憲積觸醖鹹 )	-	2015-10-15